Reduction in LDL-C following treatment with inclisiran at 2 months in a single centre lipid clinic cohort

Background and Aims: Inclisiran is a new first in class small interfering RNA (siRNA) lipid lowering drug that has been shown to be effective in reducing low-density lipoprotein cholesterol (LDL-c) in randomised controlled trials. However, real-world data of its use is currently lacking. We aimed to analyse the early effects of this drug in a tertiary centre lipid clinic.

Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: P. Padam, L. Barton, S. Wilson, A. David, S. Walji, F. De Lorenzo, K. Ray, B. Jones, J. Cegla Source Type: research